{
    "id": 27024,
    "fullName": "CD79B A42V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD79B A42V (corresponds to A43V in isoform 3) lies within the Ig-like V-type domain of the Cd79b protein (UniProt.org). A42V has been identified in the scientific literature (PMID: 28619981), but has not been biochemically characterized and therefore, its effect on Cd79b protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 974,
        "geneSymbol": "CD79B",
        "terms": [
            "CD79B",
            "AGM6",
            "B29",
            "IGB"
        ]
    },
    "variant": "A42V",
    "createDate": "10/03/2017",
    "updateDate": "10/06/2019",
    "referenceTranscriptCoordinates": {
        "id": 108741,
        "transcript": "NM_000626",
        "gDna": "chr17:g.63930379G>A",
        "cDna": "c.125C>T",
        "protein": "p.A42V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12105,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with primary central nervous system lymphoma harboring CARD11 R337Q, CD79B A42V (A43V), CD79B M163I (M164I), and MYD88 V217F demonstrated a partial response when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 28410,
                "profileName": "CARD11 R337Q CD79B A42V CD79B M163I MYD88 V217F"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28403,
            "profileName": "CD79B A42V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28410,
            "profileName": "CARD11 R337Q CD79B A42V CD79B M163I MYD88 V217F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 108741,
            "transcript": "NM_000626",
            "gDna": "chr17:g.63930379G>A",
            "cDna": "c.125C>T",
            "protein": "p.A42V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}